JP2017538680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538680A5 JP2017538680A5 JP2017525120A JP2017525120A JP2017538680A5 JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5 JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- recurrence
- therapeutic agent
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075532P | 2014-11-05 | 2014-11-05 | |
| US62/075,532 | 2014-11-05 | ||
| PCT/US2015/059297 WO2016073759A1 (en) | 2014-11-05 | 2015-11-05 | Combination immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538680A JP2017538680A (ja) | 2017-12-28 |
| JP2017538680A5 true JP2017538680A5 (enExample) | 2018-12-13 |
| JP7305300B2 JP7305300B2 (ja) | 2023-07-10 |
Family
ID=55909820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525120A Active JP7305300B2 (ja) | 2014-11-05 | 2015-11-05 | 併用免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11236139B2 (enExample) |
| EP (1) | EP3215182B1 (enExample) |
| JP (1) | JP7305300B2 (enExample) |
| WO (1) | WO2016073759A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8835419B2 (en) | 2011-12-01 | 2014-09-16 | Chemocentryx, Inc. | Substituted anilines as CCR(4) antagonists |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US11236139B2 (en) | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| HRP20220237T1 (hr) * | 2016-05-20 | 2022-04-29 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| PT3463436T (pt) | 2016-06-02 | 2023-12-28 | Ultimovacs As | Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| WO2019057808A1 (en) | 2017-09-21 | 2019-03-28 | University Of Copenhagen | PEPTIDES POTENTIATING CHEMOTAXY AND USES THEREOF |
| JP2021523237A (ja) * | 2018-05-10 | 2021-09-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がん治療のためのｃｃｌ２１およびチェックポイント阻害剤 |
| MX2021002302A (es) * | 2018-08-29 | 2021-04-28 | Chemocentryx Inc | Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. |
| US20220184040A1 (en) * | 2019-03-26 | 2022-06-16 | Translational Drug Development, Llc | Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type |
| US20220280609A1 (en) * | 2019-07-17 | 2022-09-08 | The Regents Of The University Of California | Combination cancer therapy agents and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| DE69019727T2 (de) | 1989-09-21 | 1995-10-19 | Idemitsu Kosan Co | Arylstyrolpolymer und -copolymer und verfahren zu ihrer herstellung. |
| WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| AU2002256268A1 (en) | 2001-04-18 | 2002-11-05 | The Regents Of The University Of California | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20110059137A1 (en) | 2008-03-21 | 2011-03-10 | H. Lee Moffitt Cancer Center And Research Institutute, Inc | Chemokine gene-modified cells for cancer immunotherapy |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| US11236139B2 (en) | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017151524A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods and systems for evaluating tumor mutational burden |
| KR20190141695A (ko) * | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| JP2021523237A (ja) | 2018-05-10 | 2021-09-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がん治療のためのｃｃｌ２１およびチェックポイント阻害剤 |
-
2015
- 2015-11-05 US US15/524,740 patent/US11236139B2/en active Active
- 2015-11-05 WO PCT/US2015/059297 patent/WO2016073759A1/en not_active Ceased
- 2015-11-05 JP JP2017525120A patent/JP7305300B2/ja active Active
- 2015-11-05 EP EP15856689.3A patent/EP3215182B1/en active Active
-
2022
- 2022-01-18 US US17/577,973 patent/US20220162279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hilmi et al. | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? | |
| Van Limbergen et al. | Combining radiotherapy with immunotherapy: the past, the present and the future | |
| Kershaw et al. | Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment | |
| JP2018502120A5 (enExample) | ||
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Van der Jeught et al. | Targeting the tumor microenvironment to enhance antitumor immune responses | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| Heindryckx et al. | Targeting the tumor stroma in hepatocellular carcinoma | |
| IL318946A (en) | Combinations of checkpoint inhibitors and cancer drugs | |
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| JP2016527286A5 (enExample) | ||
| JP2012196206A5 (enExample) | ||
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| JP2018023397A5 (enExample) | ||
| Haddad et al. | Using viral vectors to deliver local immunotherapy to glioblastoma | |
| JP2019517508A5 (enExample) | ||
| Murthy et al. | Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy | |
| Giavedoni et al. | Acne fulminans successfully treated with cyclosporine and isotretinoin | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances | |
| Bolm et al. | Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer | |
| JP2022542802A5 (enExample) | ||
| Fatemi et al. | Emerging frontiers in colorectal cancer therapy: From targeted molecules to immunomodulatory breakthroughs and cell-based approaches | |
| Ji et al. | Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors | |
| Shannon et al. | Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии |